FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β

eLife

Volumn 4, Issue AUGUST2015, 2015, Pages

  Gao, Chenxi ^a,b   Chen, Guangming ^a,b   Kuan, Shih Fan ^a   Zhang, Dennis Han ^c   Schlaepfer, David D ^d   Hu, Jing ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c Department of Pathology University of Pittsburgh School of Medicine ^*  (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; BETA CATENIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; FOCAL ADHESION KINASE 2; GLYCOGEN SYNTHASE KINASE 3BETA; PF 562271; WNT PROTEIN; WNT3A PROTEIN; FOCAL ADHESION KINASE 1; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, HUMAN; GSK3B PROTEIN, MOUSE; PTK2 PROTEIN, HUMAN;

ADENOMA; ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CELL CULTURE; CELL PROLIFERATION ASSAY; COLON POLYPOSIS; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; INTESTINE TUMOR; LENTIVIRUS INFECTION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RETROVIRUS INFECTION; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; UBIQUITINATION; ANIMAL; C57BL MOUSE; CARCINOGENESIS; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; METABOLISM; NUDE MOUSE; PATHOLOGY; WNT SIGNALING PATHWAY;

ANIMALS; CARCINOGENESIS; COLORECTAL NEOPLASMS; FEMALE; FOCAL ADHESION KINASE 1; FOCAL ADHESION KINASE 2; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; WNT SIGNALING PATHWAY;

EID: 84940975231     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.10072     Document Type: Article

References (42)

1. Ashton GH, Morton JP, Myant K, Phesse TJ, Ridgway RA, Marsh V, Wilkins JA, Athineos D, Muncan V, Kemp R, Neufeld K, Clevers H, Brunton V, Winton DJ, Wang X, Sears RC, Clarke AR, Frame MC, Sansom OJ. 2010. Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Developmental Cell 19:259–269. doi: 10.1016/j.devcel.2010.07.015.
2. Avraham S, London R, Fu Y, Ota S, Hiregowdara D, Li J, Jiang S, Pasztor LM, White RA, Groopman JE. 1995. Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. The Journal of Biological Chemistry 270:27742–27751.
3. Avraham H, Park SY, Schinkmann K, Avraham S. 2000. RAFTK/Pyk2-mediated cellular signalling. Cellular Signalling 12:123–133. doi: 10.1016/S0898-6568(99)00076-5.
4. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. 2004. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6:497–506. doi: 10.1016/j.ccr.2004.09.032.
5. Buescher JL, Phiel CJ. 2010. A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity. The Journal of Biological Chemistry 285:7957–7963. doi: 10.1074/jbc.M109.091603.
6. Cance WG, Kurenova E, Marlowe T, Golubovskaya V. 2013. Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics. Science Signaling 6:pe10. doi: 10.1126/scisignal.2004021.
7. Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337. doi: 10.1038/nature11252.
8. Cardozo T, Pagano M. 2004. The SCF ubiquitin ligase: insights into a molecular machine. Nature Reviews. Molecular Cell Biology 5:739–751. doi: 10.1038/nrm1471.
9. Carothers AM, Javid SH, Moran AE, Hunt DH, Redston M, Bertagnolli MM. 2006. Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Experimental Cell Research 312:387–400. doi: 10.1016/j.yexcr.2005.11.019.
10. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh DA, Schlaepfer DD. 2012. VEGF-induced vascular permeability is mediated by FAK. Developmental Cell 22:146–157. doi: 10.1016/j.devcel.2011.11.002.
11. Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimm DL. 2001. Tissue microarray analysis of betacatenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clinical Cancer Research 7:4013–4020.
12. Cole A, Frame S, Cohen P. 2004. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. The Biochemical Journal 377:249–255. doi: 10.1042/bj20031259.
13. Dajani R, Fraser E, Roe SM, Yeo M, Good VM, Thompson V, Dale TC, Pearl LH. 2003. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. The EMBO Journal 22: 494–501. doi: 10.1093/emboj/cdg068.
14. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. 2007. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Developmental Cell 12:957–971. doi: 10.1016/j.devcel.2007.04.001.
15. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759–767. doi: 10.1016/0092-8674(90)90186-I.
16. Gao C, Chen G, Romero G, Moschos S, Xu X, Hu J. 2014a. Induction of Gsk3beta-beta-TrCP interaction is required for late phase stabilization of beta-catenin in canonical Wnt signaling. The Journal of Biological Chemistry 289: 7099–7108. doi: 10.1074/jbc.M113.532606.
17. Gao C, Xiao G, Hu J. 2014b. Regulation of Wnt/beta-catenin signaling by posttranslational modifications. Cell & Bioscience 4:13. doi: 10.1186/2045-3701-4-13.
18. Gould TD, Gray NA, Manji HK. 2003. Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacological Research 48:49–53.
19. Grassilli E, Narloch R, Federzoni E, Ianzano L, Pisano F, Giovannoni R, Romano G, Masiero L, Leone BE, Bonin S, Donada M, Stanta G, Helin K, Lavitrano M. 2013. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clinical Cancer Research 19:3820–3831. doi: 10.1158/1078-0432.CCR-12-3289.
20. Hernandez AR, Klein AM, Kirschner MW. 2012. Kinetic responses of beta-catenin specify the sites of Wnt control. Science 338:1337–1340. doi: 10.1126/science.1228734.
21. Huang D, Cheung AT, Parsons JT, Bryer-Ash M. 2002. Focal adhesion kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes. The Journal of Biological Chemistry 277:18151–18160. doi: 10.1074/jbc.M104252200.
22. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. 1993. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. The EMBO Journal 12:803–808.
23. Kim SE, Huang H, Zhao M, Zhang X, Zhang A, Semonov MV, MacDonald BT, Zhang X, Garcia Abreu J, Peng L, He X. 2013. Wnt stabilization of beta-catenin reveals principles for morphogen receptor-scaffold assemblies. Science 340:867–870. doi: 10.1126/science.1232389.
24. Konstantinidou G, Ramadori G, Torti F, Kangasniemi K, Ramirez RE, Cai Y, Behrens C, Dellinger MT, Brekken RA, Wistuba II, Heguy A, Teruya-Feldstein J, Scaglioni PP. 2013. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discovery 3:444–457. doi: 10.1158/2159-8290.CD-12-0388.
25. Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJ, Maurice MM, Mahmoudi T, Clevers H. 2012. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 149:1245–1256. doi: 10.1016/j.cell.2012.05.002.
26. Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, Larocque N, Fisher SJ, Schlaepfer DD, Ilic D. 2008. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Molecular Cell 29:9–22. doi: 10.1016/j.molcel.2007.11.031.
27. Lim ST, Chen XL, Tomar A, Miller NL, Yoo J, Schlaepfer DD. 2010. Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation. The Journal of Biological Chemistry 285:21526–21536. doi: 10.1074/jbc.M110.129999.
28. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan JL. 2009. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Research 69:466–474. doi: 10.1158/0008-5472.CAN-08-3078.
29. McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D’Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko ZN, Cocco L, Martelli AM, Cervello M. 2014. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5:2881–2911.
30. McLean GW, Komiyama NH, Serrels B, Asano H, Reynolds L, Conti F, Hodivala-Dilke K, Metzger D, Chambon P, Grant SG, Frame MC. 2004. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes & Development 18:2998–3003. doi: 10.1101/gad.316304.
31. Mitra SK, Hanson DA, Schlaepfer DD. 2005. Focal adhesion kinase: in command and control of cell motility. Nature Reviews. Molecular Cell Biology 6:56–68. doi: 10.1038/nrm1549.
32. Park SY, Avraham HK, Avraham S. 2004. RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner. The Journal of Biological Chemistry 279:33315–33322. doi: 10.1074/jbc.M313527200.
33. Piedra J, Miravet S, Castano J, Pálmer HG, Heisterkamp N, García de Herreros A, Dunãch M. 2003. p120 cateninassociated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alphacatenin interaction. Molecular and Cellular Biology 23:2287–2297. doi: 10.1128/MCB.23.7.2287-2297.2003.
34. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. 2009. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. The Journal of Clinical Investigation 119:252–266. doi: 10.1172/JCI37160.
35. Sahasrabuddhe AA, Chen X, Chung F, Velusamy T, Lim MS, Elenitoba-Johnson KS. 2015. Oncogenic Y641 mutations in EZH2 prevent Jak2/beta-TrCP-mediated degradation. Oncogene 34:445–54. doi: 10.1038/onc.2013.571.
36. Sayas CL, Ariaens A, Ponsioen B, Moolenaar WH. 2006. GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. Molecular Biology of the Cell 17:1834–1844. doi: 10.1091/mbc.E05-07-0688.
37. Schaller MD. 2010. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. Journal of Cell Science 123:1007–1013. doi: 10.1242/jcs.045112.
38. Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler SJ, Zeleznik-Le NJ, Zhang J, Qiu W. 2015. FAK is required for c-Met/beta-catenin-driven hepatocarcinogenesis. Hepatology 61:214–26. doi: 10.1002/hep.27402.
39. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. 1998. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Research 58:1130–1134.
40. Sulzmaier FJ, Jean C, Schlaepfer DD. 2014. FAK in cancer: mechanistic findings and clinical applications. Nature Reviews. Cancer 14:598–610. doi: 10.1038/nrc3792.
41. Wu D, Pan W. 2010. GSK3: a multifaceted kinase in Wnt signaling. Trends in Biochemical Sciences 35:161–168. doi: 10.1016/j.tibs.2009.10.002.
42. Zhang Y, Qiu WJ, Liu DX, Neo SY, He X, Lin SC. 2001. Differential molecular assemblies underlie the dual function of Axin in modulating the WNT and JNK pathways. The Journal of Biological Chemistry 276:32152–32159. doi: 10.1074/jbc.M104451200.